Clinical Study
Effect of Telmisartan on Cerebral and Systemic Haemodynamics in Patients with Recent Ischaemic Stroke: A Randomised Controlled Trial
Table 1
Baseline characteristics by treatment group. Mean (standard deviation) or frequency (%).
| | Variable | Telmisartan | Placebo |
| | Subjects | 12 | 7 | | Age (years) | 71.9 (12.9) | 68.3 (15.6) | | Sex (male) | 10 (83) | 4 (57) | Systolic BP
(at randomisation, mmHg) | 165.7 (12.5) | 166.0 (16.7) | | Previous hypertension | 6 (50) | 5 (71) | | Previous stroke | 1 (8) | 1 (14) | | Previous diabetes mellitus | 0 (0) | 2 (29) | | Previous atrial fibrillation | 3 (25) | 1 (14) | | Previous ischaemic heart disease | 2 (17) | 2 (29) | | Previous high cholesterol | 4 (33) | 4 (57) | | Smoking status | | | | Current | 2 (17) | 2 (29) | | Past | 5 (42) | 5 (71) | | Never | 5 (42) | 0 (0) | | Time to baseline scan (hours) | 57.9 (20.1) | 67.8 (21.5) | | Scandinavian Stroke Scale (/58) | 48.1 (11.8) | 47.9 (8.1) | | Cortical syndrome (OCSP) | 7 (59) | 1 (14) | | Prestroke antihypertensive treatment | 5 (42) | 4 (57) | | Diuretic | 1 (8) | 2 (22) | | Beta blocker | 5 (42) | 1 (11) | | Alpha-blocker | 0 | 2 (22) | | Angiotensin receptor blocker | 2 (17) | 0 | | ACE inhibitor | 0 | 2 (22) | | Calcium channel antagonist | 1 (8) | 2 (22) | | Other | 0 | 0 |
|
|
OCSP: Oxford community stroke project.
|
